natgillin/translations-raw huggingface dataset:
Results are presented in Table 11. 
Rezultati so predstavljeni v preglednici 11.
The efficacy results of bevacizumab in combination with IFL-chemotherapy are displayed in Table 4. 
Rezultate učinkovitosti bevacizumaba v kombinaciji z kemoterapijo po shemi IFL prikazuje preglednica 4.
Three additional studies with bevacizumab have been conducted in mCRC patients: first-line (NO16966), second-line with no previous bevacizumab treatment (E3200), and second-line with previous bevacizumab treatment following disease progression in first-line (ML18147). 
Z bevacizumabom so pri bolnikih z mCRC izvedli 3 dodatne študije: v prvi liniji zdravljenja (NO16966), v drugi liniji zdravljenja brez predhodnega zdravljenja z bevacizumabom (E3200) in v drugi liniji zdravljenja, kjer so bolniki predhodno prejemali bevacizumab v prvi liniji, nato pa je njihova bolezen napredovala (ML18147).
• symptoms that suggest changes in normal brain function (headaches, vision changes, confusion, or seizures), and high blood pressure, 
• simptome, ki kažejo na spremembe v normalnem delovanju možganov (glavoboli, spremembe vida, zmedenost ali epileptični napadi), in visok krvni tlak,
In study JO25567, all grade hypertension was observed in 77.3% of the patients who received bevacizumab in combination with erlotinib as first-line treatment for non-squamous NSCLC with EGFR activating mutations, compared to 14.3% of patients treated with erlotinib alone. 
V študiji JO25567 so hipertenzijo vseh stopenj opazili pri 77,3 % bolnikov, ki so prejemali bevacizumab v kombinaciji z erlotinibom kot prvo linijo zdravljenja neploščatoceličnega NSCLC z EGFR-aktivirajočimi mutacijami, v primerjavi s 14,3 % bolnikov, ki so se zdravili samo z erlotinibom.
Advanced and/or metastatic renal cell cancer (mRCC) 
Napredovali in/ali metastatski rak ledvičnih celic (mRCC - metastatic renal cell cancer)
● serious infections of the skin or deeper layers under the skin, 
● resne okužbe kože ali globljih plasti pod kožo,
The trial contained two parts: an initial unblinded 2-arm part (Part I) in which patients were randomised to two different treatment groups (XELOX and FOLFOX-4) and a subsequent 2 x 2 factorial 4-arm part (Part II) in which patients were randomised to four treatment groups (XELOX + placebo, FOLFOX-4 + placebo, XELOX + bevacizumab, FOLFOX-4 + bevacizumab). 
Preskušanje je obsegalo 2 dela: v začetnem, odprtem delu z 2 skupinama (1. del) so bolnike randomizirali v 2 različni skupini zdravljenja (XELOX in FOLFOX-4), v poznejšem delu s 4 skupinami in faktorskim načrtom 2 × 2 (2. del) pa so bolnike randomizirali v 4 skupine zdravljenja (XELOX + placebo, FOLFOX-4 + placebo, XELOX + bevacizumab, FOLFOX4 + bevacizumab).
Table 3 Adverse reactions reported in post-marketing setting 
Preglednica 3 Neželeni učinki, o katerih so poročali v obdobju trženja
• redness, peeling, tenderness, pain, or blistering on the fingers or feet, 
• rdečino, luščenje, občutljivost, bolečina ali pojav mehurjev na prstih ali stopalih,
What Zirabev is and what it is used for 
Kaj je zdravilo Zirabev in za kaj ga uporabljamo
Pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. 
Bolečina v ustih, zobeh in/ali čeljusti, otekline ali razjede v ustih, odrevenelost ali občutek teže v čeljusti ali razmajanost zoba.
Results from the primary analysis and the follow-up analysis are presented by bevacizumab Treatment and by Trial Treatment in Table 14 and Table 15, respectively. 
Rezultati primarne analize in nadaljnje analize spremljanja glede na zdravljenje z bevacizumabom in zdravljenje v okviru preskušanja so predstavljeni v preglednici 14 oziroma preglednici 15.
Cisplatin/Gemcitabine + placebo 
Cisplatin in gemcitabin + placebo
Table 14 Efficacy results from study GOG-0240 by bevacizumab treatment 
Preglednica 14 Rezultati učinkovitosti v študiji GOG-0240 glede na zdravljenje z bevacizumabom
Before you are given Zirabev or while you are being treated with Zirabev: 
Preden prejmete zdravilo Zirabev ali med zdravljenjem z zdravilom Zirabev:
The most frequently observed adverse reactions across clinical trials in patients receiving bevacizumab were hypertension, fatigue or asthenia, diarrhoea and abdominal pain. 
Najpogostnejši neželeni učinki, ki so jih opazili v kliničnih preskušanjih pri bolnikih, ki so se zdravili z bevacizumabom, so bili hipertenzija, utrujenost ali astenija, diareja in bolečina v trebuhu.
Most of the patients who experienced CHF had metastatic breast cancer and had received previous treatment with anthracyclines, prior radiotherapy to the left chest wall or other risk factors for CHF were present. 
Večina bolnikov, pri katerih se je pojavilo KSP, je imela metastatski rak dojk in je predhodno prejemala zdravljenje z antraciklini, zdravljenje z obsevanjem leve strani prsnega koša ali pa so pri njih obstajali drugi dejavniki tveganja za KSP.
GI-vaginal fistulae in study GOG-0240 
Fistule med prebavili in nožnico v študiji GOG-0240
Zirabev has been developed and made to treat cancer by injecting it into the bloodstream. 
Zdravilo Zirabev so razvili in izdelali za zdravljenje raka z injiciranjem v krvni obtok.
a 5.0 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks 
5,0 mg/kg vsaka 2 tedna ali 7,5 mg/kg vsake 3 tedne
In Study BO20924, bevacizumab exposure was generally lower compared to a typical adult patient at the same dose. 
V študiji BO20924 je bila izpostavljenost bevacizumabu v splošnem manjša kot pri tipičnem odraslem bolniku, ki je prejemal enak odmerek.
Bevacizumab has been associated with serious cases of gastrointestinal perforation. 
Bevacizumab je povezan z resnimi primeri perforacije prebavil.
The addition of bevacizumab to IFN-alpha-2a significantly increased PFS and objective tumour response rate. 
Dodajanje bevacizumaba k IFN-alfa-2a je pomembno podaljšalo PFS in pomembno povečalo objektivni odziv tumorja na zdravljenje.
Administration of bevacizumab or its parental murine antibody to xenotransplant models of cancer in nude mice resulted in extensive anti-tumour activity in human cancers, including colon, breast, 
Injiciranje bevacizumaba ali njegovega izvornega mišjega protitelesa v heterotransplantatne modele raka pri golih miškah je povzročilo obsežno protitumorsko aktivnost v tumorjih človeškega izvora,
• an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections), 
• razširitev in oslabitev stene krvne žile ali raztrganina v steni krvne žile (anevrizme in disekcije arterij),
● It is possible that Zirabev can increase the risk of bleeding in your lungs, including coughing or spitting blood. 
● Možno je, da zdravilo Zirabev poveča tveganje za krvavitev v pljučih, vključno z izkašljevanjem ali pljuvanjem krvi.
A total of 116 patients were randomised to receive bevacizumab 3 mg/kg every 2 weeks (n=39), 10 mg/kg every 2 weeks; (n=37), or placebo (n=40). 
Skupno so randomizirali 116 bolnikov na bevacizumab v odmerku 3 mg/kg vsaka 2 tedna (n = 39), bevacizumab v odmerku 10 mg/kg vsaka 2 tedna (n = 37) ali placebo (n = 40).
95% CI for difference in response rates p-value (Chi-squared test) 
95 % IZ za stopnje odziva razlika v stopnjah odziva 95 % IZ za razliko v stopnjah odziva p-vrednost (test hi-kvadrat)
b For additional information refer below within section “Further information on selected serious adverse reactions” 
Za dodatne informacije glejte poglavje ''Dodatne informacije o določenih resnih neželenih učinkih'' v nadaljevanju.
Median PFS (on treatment)** 
Sekundarni opazovani dogodki mediano PFS (med zdravljenjem)**
• serious infections of the skin or deeper layers under the skin, especially if you had holes in the gut wall or problems with wound healing, 
• resne okužbe kože ali globljih plasti pod kožo, zlasti če ste imeli preluknjano črevesno steno ali težave pri celjenju ran,
Analyses of the clinical safety data suggest that the occurrence of hypertension and proteinuria with bevacizumab therapy are likely to be dose-dependent. 
Analize kliničnih podatkov o varnosti kažejo, da je pojav hipertenzije in proteinurije med zdravljenjem z bevacizumabom verjetno odvisen od njegovega odmerka.
EGFR monoclonal antibodies should not be administered for the treatment of mCRC in combination with bevacizumab-containing chemotherapy. 
Monoklonskih protiteles proti EGFR za zdravljenje mCRC ne smemo uporabljati v kombinaciji s kemoterapijo, ki vključuje bevacizumab.
At the time of the final primary analysis, the primary endpoint of EFS by independent central review did not show a statistically significant difference between the two treatment arms, with HR of 0.93 (95% CI: 0.61, 1.41; p-value = 0.72). 
Neodvisni centralni pregled primarnega opazovanega dogodka EFS v času končne primarne analize ni pokazal statistično pomembne razlike med zdravljenima skupinama; HR je bilo 0,93 (95 % IZ: 0,61; 1,41; p-vrednost = 0,72).
The efficacy results are presented in Table 12. 
Rezultati učinkovitosti so predstavljeni v preglednici 12.
Hypersensitivity reactions and infusion reactions (not known); with the following possible co-manifestations: dyspnoea/difficulty breathing, flushing/redness/rash, hypotension or hypertension, oxygen desaturation, chest pain, rigors and nausea/vomiting (see also section 4.4 and Hypersensitivity reactions/infusion reactions above) 
Bolezni imunskega sistema preobčutljivostne reakcije in reakcije na infuzijo (neznana); z naslednjimi možnimi znaki: dispneja/težko dihanje, vročinski oblivi/rdečina/izpuščaj, hipotenzija ali hipertenzija, zmanjšana nasičenost s kisikom, bolečina v prsnem košu, okorelost in navzea/bruhanje (glejte tudi poglavje 4.4 in ''Preobčutljivostne reakcije/reakcije na infuzijo'' zgoraj)
Metastatic breast cancer (mBC) 
Metastatski rak dojk (mBC - metastatic breast cancer)
Zirabev is for single-use only, as the product contains no preservatives. 
Zdravilo Zirabev je le za enkratno uporabo, saj ne vsebuje konzervansov.
The clinical benefit of bevacizumab as measured by PFS was seen in all pre-specified subgroups tested (including disease-free interval, number of metastatic sites, prior receipt of adjuvant chemotherapy and oestrogen receptor (ER) status). 
Klinično korist bevacizumaba, ki so jo izmerili glede na PFS, so opazili v vseh preiskovanih, vnaprej določenih podskupinah (vključno z intervalom brez bolezni, številom metastatskih mest, predhodnim prejemanjem adjuvantne kemoterapije in statusom estrogenskih receptorjev (ER)).
Your doctor should advise you about using contraception during treatment with Zirabev and for at least 6 months after the last dose of Zirabev. 
Zdravnik vam mora svetovati, da med zdravljenjem z zdravilom Zirabev in še najmanj 6 mesecev po zadnjem odmerku zdravila Zirabev uporabljate kontracepcijo.
There were neither statistically significant nor clinically relevant differences in bevacizumab clearance in patients receiving bevacizumab monotherapy compared to patients receiving bevacizumab in combination with interferon alfa-2a, erlotinib or chemotherapies (IFL, 5-FU/LV, carboplatin/paclitaxel, capecitabine, doxorubicin or cisplatin/gemcitabine). 
Pri bolnikih, ki so prejemali bevacizumab v monoterapiji, ni bilo statistično ali klinično pomembnih razlik v očistku bevacizumaba v primerjavi z bolniki, ki so prejemali bevacizumab v kombinaciji z interferonom alfa-2a, erlotinibom ali kemoterapevtiki (IFL, 5-FU/LV, karboplatin/paklitaksel, kapecitabin, doksorubicin ali cisplatin/gemcitabin).
You could also experience redness or flushing of the skin or a rash, chills and shivering, feeling sick (nausea) or being sick (vomiting). 
Lahko se pojavi tudi rdečina ali zardevanje kože ali izpuščaj, mrzlica in drgetanje, občutek siljenja na bruhanje (navzea) ali bruhanje.
During the trial, of the patients who received trial treatment, 32.2% (136/422) of patients received 7-12 administrations of bevacizumab and 21.1% (89/422) of patients received 13 or more administrations of bevacizumab. 
Med preskušanjem je od bolnikov, ki so prejemali zdravljenje v okviru preskušanja, 32,2 % (136/422) bolnikov prejelo 7-12 odmerkov bevacizumaba, 21,1 % (89/422) bolnikov pa je prejelo 13 ali več odmerkov bevacizumaba.
There is evidence suggesting that all Grade (US National Cancer Institute- Common Terminology Criteria for Adverse Events [NCI-CTCAE v.3]) proteinuria may be related to the dose. 
Obstajajo dokazi, ki kažejo, da je proteinurija vseh stopenj [Merila NCI za poenoteno terminologijo neželenih dogodkov, različica 3.0 (NCI-CTCAE v.3)] lahko povezana z odmerkom.
In two subsequent studies in patients with treated brain metastases (which included around 800 patients), one case of Grade 2 CNS haemorrhage was reported in 83 subjects treated with bevacizumab (1.2%) at the time of interim safety analysis (NCI-CTCAE v.3). 
V 2 kasnejših študijah pri bolnikih z zdravljenimi metastazami v možganih (ki sta vključevali približno 800 bolnikov) so v času vmesne analize varnosti poročali o 1 primeru krvavitve v CŽS stopnje 2 pri skupno 83 preskušancih, ki so se zdravili z bevacizumabom (1,2 %) (NCI-CTCAE v.3).
In four phase III trials (AVF2119g, E2100, BO17708 and AVF3694g) in patients with metastatic breast cancer CHF Grade 3 (NCI-CTCAE v.3) or higher was reported in up to 3.5% of patients treated with bevacizumab in combination with chemotherapy compared with up to 0.9% in the control arms. 
V 4 preskušanjih 3. faze (AVF2119g, E2100, BO17708 in AVF3694g) pri bolnikih z metastatskim rakom dojk so o KSP 3. ali višje stopnje (NCI-CTCAE v.3) poročali pri največ 3,5 % bolnikov, ki so se zdravili z bevacizumabom v kombinaciji s kemoterapijo, v primerjavi z največ 0,9 % bolnikov v kontrolnih skupinah.
In cases of internal fistula not arising in the gastrointestinal tract, discontinuation of Zirabev should be considered. 
V primerih notranjih fistul, ki ne izhajajo iz prebavil, je treba razmisliti o prekinitvi zdravljenja z zdravilom Zirabev.
Stopping your treatment with Zirabev may stop the effect on tumour growth. 
Prekinitev zdravljenja z zdravilom Zirabev lahko ustavi učinek na rast tumorja.
This group of medical terms may involve the same underlying pathophysiology (e.g. arterial thromboembolic reactions include cerebrovascular accident, myocardial infarction, transient ischaemic attack and other arterial thromboembolic reactions). 
Ta skupina medicinskih izrazov lahko zajema enako osnovno patofiziologijo (npr. arterijski trombembolični dogodki vključujejo cerebrovaskularni insult, miokardni infarkt, prehodno možgansko ishemijo ter druge arterijske trombembolične dogodke).
In clinical trials, with the exception of study JO25567, the overall incidence of hypertension (all grades) ranged up to 42.1% in the bevacizumab containing arms compared with up to 14% in the control arms. 
V kliničnih preskušanjih, z izjemo študije JO25567, je bila celokupna pojavnost hipertenzije (vseh stopenj) v skupinah bolnikov, ki so prejemali bevacizumab, največ 42,1 % v primerjavi z največ 14 % pri bolnikih v kontrolnih skupinah.
This condition is usually secondary to wound healing complications, gastrointestinal perforation or fistula formation. 
To stanje je običajno posledica zapletov pri celjenju ran, perforacije prebavil ali nastanka fistule.
• Seeing flashes of light with floaters, progressing to a loss of some of your vision, 
• bliskanje v vidnem polju z motnjavami, kar lahko napreduje do delne izgube vida,
• allergic reactions (the signs may include difficulty breathing, facial redness, rash, low blood pressure or high blood pressure, low oxygen in your blood, chest pain, or nausea/vomiting), 
• alergijske reakcije (znaki lahko vključujejo oteženo dihanje, rdečino na obrazu, izpuščaj, nizek ali visok krvni tlak, nizko raven kisika v krvi, bolečino v prsnem košu in siljenje na bruhanje/bruhanje),
• feeling of numbness or tingling in hands or feet, 
• občutek odrevenelosti ali mravljinčenja v dlaneh ali stopalih,
Duration of response Median time (months) 
p-vrednost Trajanje odziva mediani čas (meseci)
A third group of 110 patients received bolus 5-FU/FA + bevacizumab (Arm 3). 
Tretja skupina 110 bolnikov je prejemala bolus 5-FU/FA + bevacizumab (skupina 3).
The overall incidence of NCI-CTC Grade 3 and 4 hypertension in patients receiving bevacizumab ranged from 0.4% to 17.9%. 
Celokupna pojavnost hipertenzije stopnje 3 in 4 po NCICTC je bila pri bolnikih, ki so se zdravili z bevacizumabom, od 0,4 % do 17,9 %.
The rate of infusion was based on tolerability, with an initial infusion duration of 90 minutes. 
Hitrost infundiranja je bila odvisna od prenašanja; prva infuzija je trajala 90 minut.
The study did not meet its primary endpoint of demonstrating a significant improvement of EFS (Central Radiology Review Committee (CRRC)-assessed) when bevacizumab was added to the RT/T arm compared with RT/T alone (HR = 1.44; 95% CI: 0.90, 2.30). 
V študiji niso izpolnili primarnega opazovanega dogodka, tj. dokazati pomembno izboljšanje preživetja brez dogodkov (EFS - event-free survival) (po oceni odbora za centralni radiološki pregled (CRRC - Central Radiology Review Committee)) v skupini, ki je poleg RT/T prejemala še bevacizumab, v primerjavi s skupino, ki je prejemala samo RT/T (HR = 1,44; 95 % IZ: 0,90; 2,30).
In randomised clinical trials, age > 65 years was associated with an increased risk of developing arterial thromboembolic reactions, including cerebrovascular accidents (CVAs), transient ischaemic attacks (TIAs) and myocardial infarctions (MIs). 
V randomiziranih kliničnih preskušanjih je bila starost > 65 let povezana s povečanim tveganjem za razvoj arterijskih trombemboličnih dogodkov, vključno s cerebrovaskularnimi insulti (CVI), prehodnimi možganskimi ishemijami (TIA - transient ischaemic attack) in miokardnimi infarkti (MI).
Presentation may include seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension. 
Ta motnja se lahko kaže z epileptičnimi napadi, glavoboli, spremenjenim duševnim stanjem, motnjami vida ali kortikalno slepoto s sočasno hipertenzijo ali brez nje.
In patients in AVF3694g who received treatment with anthracyclines and who had not received anthracyclines before, no increased incidence of all Grade CHF was observed in the anthracycline + bevacizumab group compared to the treatment with anthracyclines only. 
V preskušanju AVF3694g pri bolnikih, ki so prejemali zdravljenje z antraciklini in ki se predhodno še niso zdravili z antraciklini, v skupini z antraciklinom in bevacizumabom niso opazili povečane incidence KSP katerekoli stopnje v primerjavi s skupino, ki se je zdravila samo z antraciklini.
In NSABP C-08, a phase III trial of bevacizumab in adjuvant treatment of patients with colon cancer, the incidence of new cases of ovarian failure, defined as amenorrhoea lasting 3 or more months, FSH level ≥ 30 mIU/mL and a negative serum β-HCG pregnancy test, has been evaluated in 295 premenopausal women. 
V preskušanju NSABP C-08, preskušanju 3. faze bevacizumaba pri adjuvantnem zdravljenju bolnikov z rakom debelega črevesa, so pojavnost novih primerov okvare jajčnikov, ki so jo opredelili kot amenoreja, ki traja 3 mesece ali dlje, raven folikle stimulirajočega hormona (FSH) ≥ 30 mi.e./ml in negativen test nosečnosti z merjenjem prisotnosti beta humanega horijevega gonadotropina (βHCG) v serumu, ocenjevali pri 295 ženskah pred menopavzo.
Your doctor will prescribe a dose of Zirabev that is right for you. 
Zdravnik vam bo predpisal ustrezni odmerek zdravila Zirabev.
IgGs are known to cross the placenta, and bevacizumab is anticipated to inhibit angiogenesis in the foetus, and thus is suspected to cause serious birth defects when administered during pregnancy. 
Znano je, da imunoglobulini razreda G (IgG) prehajajo skozi placento, zato lahko predvidevamo, da bevacizumab zavira angiogenezo pri plodu in tako domnevno povzroča resne okvare ploda, če ga dajemo med nosečnostjo.
New cases of ovarian failure were reported in 2.6% patients in the mFOLFOX-6 group compared to 39% in the mFOLFOX-6 + bevacizumab group. 
O novih primerih okvare jajčnikov so poročali pri 2,6 % bolnic v skupini, ki se je zdravila po shemi mFOLFOX-6, v primerjavi z 39 % bolnic v skupini, ki se je zdravila po shemi mFOLFOX-6 in bevacizumabom.
Limited information is available on the continued use of bevacizumab in patients with other fistulae. 
Podatki o nadaljnji uporabi bevacizumaba pri bolnikih z drugimi fistulami so omejeni.
Objective response rate (ORR) Patients included in analysis Rate 
Objektivni odziv na zdravljenje (ORRobjective response rate) število bolnikov, vključenih v analizo delež
Use of irinotecan- or oxaliplatin-containing regimen was switched depending on first-line usage of either oxaliplatin or irinotecan. 
Shemo, ki je vključevala irinotekan ali oksaliplatin, so bolnikom zamenjali glede na to, ali so v prvi liniji uporabljali oksaliplatin ali irinotekan.
The use of diuretics to manage hypertension is not advised in patients who receive a cisplatin-based chemotherapy regimen. 
Uporaba diuretikov za uravnavanje hipertenzije pri bolnikih, ki prejemajo kemoterapijo na osnovi cisplatina, ni priporočljiva.
Cases of Osteonecrosis of the Jaw (ONJ) have been reported in patients treated with bevacizumab, most of which occurred in patients who had identified risk factors for ONJ, in particular exposure to intravenous bisphosphonates and/or a history of dental disease requiring invasive dental procedures (see also section 4.4) 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva pri bolnikih, ki so se zdravili z bevacizumabom, so poročali o primerih osteonekroze čeljustnic; v večini primerov je šlo za bolnike, pri katerih so ugotovili dejavnike tveganja za osteonekrozo čeljustnic, zlasti izpostavljenost intravenskim bisfosfonatom in/ali zobno bolezen v anamnezi, ki je zahtevala invazivne zobozdravstvene posege (glejte tudi poglavje 4.4)
Intra-abdominal inflammatory process may be a risk factor for gastrointestinal perforations in patients with metastatic carcinoma of the colon or rectum, therefore, caution should be exercised when treating these patients. 
Vnetni proces v trebušni votlini je lahko dejavnik tveganja za perforacijo prebavil pri bolnikih z metastatskim karcinomom debelega črevesa in danke, zato je med zdravljenjem teh bolnikov potrebna previdnost.
Possible risk factors include squamous cell histology, treatment with antirheumatic/anti-inflammatory substances, treatment with anticoagulants, prior radiotherapy, bevacizumab therapy, previous medical history of atherosclerosis, central tumour location and cavitation of tumours prior to or during therapy. 
Med možnimi dejavniki tveganja so ploščatocelična histologija, zdravljenje z antirevmatiki/protivnetnimi zdravili, zdravljenje z antikoagulanti, predhodno obsevalno zdravljenje, zdravljenje z bevacizumabom, ateroskleroza v anamnezi, centralna lokalizacija tumorja in kavitacija tumorjev pred ali med zdravljenjem.
Patients with renal impairment The safety and efficacy have not been studied in patients with renal impairment (see section 5.2). 
Bolniki z ledvično okvaro Varnosti in učinkovitosti pri bolnikih z ledvično okvaro niso proučevali (glejte poglavje 5.2).
In Study BO25041, bevacizumab exposure was similar compared to a typical adult at the same dose. 
V študiji BO25041 je bila izpostavljenost bevacizumabu podobna kot pri tipičnem odraslem bolniku, ki je prejemal enak odmerek.
• problems with wound healing after surgery, 
• težave s celjenjem ran po kirurškem posegu,
Zirabev 25 mg/ml sterile concentrate bevacizumab 
Zirabev 25 mg/ml sterilni koncentrat bevacizumab i.v.
• an open sore or hole in the lining of the stomach or small intestine (the signs may include abdominal pain, feeling bloated, black tarry stools or blood in your stools (faeces) or blood in your vomit), 
• odprto razjedo ali predrtje sluznice želodca ali tankega črevesa (znaki lahko vključujejo bolečino v trebuhu, občutek napihnjenosti, črno katranasto blato ali kri v blatu (fecesu) in kri v bruhanju),